The three largest pharmacy benefit managers (PBMs) inflated the price of specialty generic drugs beyond their costs of ...
CVS Caremark, OptumRx and St. Louis-based Express Scripts — are part of huge health conglomerates that also own insurers, ...
Mattingly is an associate professor and vice chair of research in the Department of Pharmacotherapy at the University of Utah ...
The Federal Trade Commission found Pharmacy Benefit Managers profited billions by raising the prices of "specialty drugs." ...
The National Association of Chain Drug Stores is praising the Federal Trade Commission's (FTC) unanimous, 5-0, vote on Monday to release the second interim staff report on the FTC's study of big ...
FTC report reveals significant markups by top PBMs on specialty drugs, driving $7.3 billion in revenue and raising costs for ...
From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 ...
An Alabama lawmaker believes prescription care management should be a legislative priority during the upcoming session.
The Federal Trade Commission accuses CVS, Cigna and UnitedHealth of artificially inflating prices on specialty generic drugs ...
In the debate over the high cost of prescription drugs, pharmacy benefit managers are hotly contested. PBMs, the middlemen in ...
The FDC released a second highly critical report of PBMs, which may provide further impetus for legislative action to curb ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback